Maria Rosaria Domenici

TL;DR: The data presented here clearly highlight the complexity of using adenosinergic agents therapeutically in PD and other neurodegenerative disorders and point out many areas for further inquiry, and confirm that adenosine receptor ligands, particularly A2A receptor ligand, have many promising characteristics that encourage the pursuit of their therapeutic potential.

TL;DR: The adenosine A2A receptor antagonist SCH 58261 has neuroprot protective effects, although only at low doses, in an excitotoxic rat model of HD, and the inhibition of QA-evoked glutamate outflow seems to be the major mechanism underlying the neuroprotective effects.

TL;DR: This is the first evidence showing that hippocampal A2ARs and mGlu5Rs are co‐located and act synergistically, and that A2 ARs play a permissive role in mGLU5R receptor‐mediated potentiation of NMDA effects in the hippocampus.

TL;DR: Results indicate that the tonic activation of A2ARs is required for BDNF‐induced potentiation of synaptic transmission and for sustaining a normal BDNF tone in the hippocampus.

TL;DR: The data show for the first time that βA–astrocytic interaction produces a detrimental effect on neurons, which may contribute to neurodegeneration in AD.